Jornal Do Brasilia - French, US drug firms team up for Covid-flu shot

NYSE - LSE

RIO	-0.24%	62.24	$
SCS	-0.98%	10.25	$
CMSC	0.45%	22.26	$
CMSD	0.01%	22.17	$
BTI	1.94%	44.44	$
RBGPF	100%	67.2	$
BCE	0.42%	21.66	$
NGG	1.35%	73.42	$
BP	-0.68%	29.2	$
RELX	-0.07%	54.99	$
RYCEF	0.73%	11	$
BCC	-1.41%	89.92	$
VOD	7.22%	10.39	$
GSK	1.15%	38.4	$
JRI	0.23%	12.82	$
AZN	0.33%	69.92	$

French, US drug firms team up for Covid-flu shot

HEALTH 10.05.2024

French, US drug firms team up for Covid-flu shot / Photo: © AFP/File

French pharmaceutical giant Sanofi and struggling US rival Novavax announced Friday an alliance to sell a Covid vaccine and develop another that combines with a flu shot.

Text size:

Under a licensing deal worth up to $1.2 billion, the companies will co-commercialise Novavax's Covid-19 vaccine worldwide, except in some countries including India, Japan and South Korea, where the US firm already has partnership agreements.

Novavax will receive an upfront payment of $500 million and up to $700 million if it reachers certain milestones while Sanofi will take a five percent stake in the US company.

Sanofi will book sales of Novavax's protein-based Covid-19 vaccine from 2025.

The French group will be able to develop a combination flu-Covid vaccine using its own flu shots with the US company's Covid jab.

The announcement comes as pharmaceutical companies have reported drops in sales for Covid vaccines.

Novavax, which is highly dependent on its Covid vaccine, raised doubts last year about its ability to continue its business.

The Maryland-based firm was an early frontrunner in the global vaccine race, but fell behind after being hit by manufacturing and regulatory delays.

For Sanofi, the deal is a chance to develop a combination flu-Covid jab.

"With flu and Covid-19 hospital admission rates now closely mirroring each other, we have an opportunity to develop non-mRNA flu-Covid-19 combination vaccines offering patients both enhanced convenience and protection against two serious respiratory viruses," said Jean-Francois Toussaint, Sanofi's global head of vaccine research and development.

M. de Jesus--JDB

Featured

Jumbo task: 400 pills a day for elephants with TB in Pakistan

A team of doctors and vets in Pakistan has developed a novel treatment for a pair of elephants suffering from tuberculosis that involves feeding them at least 400 pills a day.

Europe increases pressure on Israel over Gaza offensive

European countries ramped up pressure on Israel to abandon its intensified campaign in Gaza and let more aid into the war-ravaged territory, where rescuers said fresh attacks killed dozens of people on Tuesday.

US limits Covid boosters to over-65s or those at high risk

The United States will limit Covid-19 boosters to people over 65 or those at risk of serious illness, while requiring vaccine makers to run fresh clinical trials before offering shots to younger and healthier individuals, officials said Tuesday.

US to limit Covid boosters to over-65s or those at high risk

The United States will limit routine Covid-19 boosters to people over 65 or those at higher risk of serious illness, while requiring new placebo-controlled trials to justify vaccines for healthy individuals under that threshold, senior health officials said Tuesday.